According to the results of Cox regression analysis, we found that ARRB2 was significantly different in lung adenocarcinoma (LUAD, P = 0.0260), pancreatic cancer (PAAD, P = 0.0155), and PRAD (P = 0.0003). This evidence concerns the gene ARRB2 and prostate adenocarcinoma.